Cytosorbents Corporation.
CTSO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
CytoSorbents Corporation is a critical care immunotherapy company specializing in blood purification. Its flagship product, CytoSorb, is designed to reduce cytokine storm and other inflammatory mediators in critically ill patients. The company focuses on developing and commercializing CytoSorb for v...Show More
Better Health for All
50
The company's core products, CytoSorb and DrugSorb-ATR, deliver transformative health benefits. CytoSorb therapy has shown a statistically significant reduction in 28-day all-cause mortality for septic shock patients, from 72% to 53% in one study of 116 patients, and an observed ICU mortality rate of 49% versus a predicted 66% in a study of 175 patients.
1
DrugSorb-ATR is designed to reduce perioperative bleeding complications during cardiothoracic surgery, addressing a critical unmet need.
2
The company's business model is exclusively focused on maximizing health benefits, with no evidence of revenue from products with negative health outcomes. CytoSorb has been used in over 250,000 treatments worldwide, with over 20,000 human treatments safely in the EU, and a study of 116 septic shock patients reported no device-related adverse events.
3
The company has received over $39.5 million in non-dilutive funding for research and development.
4
Clinical trials for DrugSorb-ATR, such as STAR-T, are described as randomized, double-blind, and sham-controlled, and the product has received FDA Breakthrough Device Designation for two indications.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Cytosorbents Corporation on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
The company has an employee rating of 3.9 out of 5 stars on Glassdoor, based on 28 anonymous reviews, which translates to an engagement score of 78%.
1
Furthermore, 69% of employees would recommend working at the company.
2
Fair Trade & Ethical Sourcing
0
No evidence was found in the provided articles regarding Cytosorbents Corporation's performance on fair trade and ethical sourcing practices. Information on supplier certifications, audit frequency, child/forced labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, use of high-risk materials, or supplier diversity spend is not available.
1
Honest & Fair Business
0
No quantitative data or specific details were provided across the articles to assess the company against the 'Honest & Fair Business' KPIs. Information regarding regulatory fines, transparency index scores, whistleblower policy strength, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policy details, or third-party verification of ethical claims was not available.
1
Several SEC filings were inaccessible due to throttling, and other corporate governance documents only outlined policies without providing performance data.
2
Kind to Animals
0
CytoSorbents plans to evaluate new polymers in a pig model of Gram-negative sepsis and will test its polymers in septic porcine plasma.
1
The company has received a $1,977,024 contract for a pre-clinical porcine study
2
and a $1,499,987 Phase II SBIR contract for research involving animal experiments.
3
The company adheres to the Animal Welfare Act Regulations and other Federal statutes relating to animal experiments, as well as the principles of the Guide for the Care and Use of Laboratory Animals.
4
No War, No Weapons
-40
The company develops the HemoDefend-BGA filter, a dual-use technology designed to improve blood transfusions for both warfighter and civilian life, applicable in both civilian and military settings.
1
This technology is developed under contracts from various defense agencies, including the Department of Defense, Defense Health Agency, U.S. Army Medical Research Acquisition Activity, and DARPA, which have provided approximately $48 million in non-dilutive funding.
2
Planet-Friendly Business
0
The provided articles focus on CytoSorbents Corporation's financial performance, product sales, regulatory approvals, and operational efficiencies such as headcount reduction and cost savings.
1
There is no information or specific data points regarding the company's environmental performance, carbon emissions, renewable energy use, waste management, water consumption, climate targets, or any other planet-friendly business initiatives.
2
Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
0
No evidence available to assess Cytosorbents Corporation on Respect for Cultures & Communities.
Safe & Smart Tech
10
The company states it collects only necessary data and anonymizes server logs after a maximum of seven days.
1
It explicitly states compliance with GDPR.
2
Users are granted rights including access, rectification, erasure, restriction of processing, objection, data portability, and complaint filing.
3
The company also states that data is encrypted before transfer.
4
Furthermore, it utilizes third-party consultants for security reviews, penetration testing, and IT audits.
5
Zero Waste & Sustainable Products
0
No specific data related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.
1